New drug approved_Alecitinib

USFDA recently approved Alecitinib, an antineoplastic agent. 

Drug name:
Alectinib
Innovator:
Hoffman-LA Roche
Brand name:
Alecensa
Chemical structure:





9-ethyl-6, 6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5 H-benzo[b]carbazole-3-carbonitrile hydrochloride

Indications:
Alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, metastatic non small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Dosage form:
Capsule; oral 
Strengths:
150mg 

Comments

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

Webinar on ‘OPPORTUNITY TO COMMERCIALIZE HERBAL RESEARCH’